Anti-influenza A antigen specific T cell therapy(Tevogen Bio)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAnti-influenza A antigen specific T cell therapy(Tevogen Bio)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicity
TargetsNot applicable
Therapy Area/IndicationsInfluenza A virus infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesTevogen Bio Inc
China Registration ClassN/A

Develop Information

Active CompaniesTevogen Bio Inc
Inactive CompaniesN/A
Active IndicationsInfluenza A virus infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A